|1.||Lokki, Marja-Liisa: 4 articles (01/2014 - 12/2009)|
|2.||Zhou, Bi: 4 articles (07/2010 - 01/2004)|
|3.||Yu, C Yung: 4 articles (06/2007 - 01/2004)|
|4.||Lhotta, Karl: 3 articles (01/2012 - 01/2004)|
|5.||Yu, C Y: 3 articles (10/2010 - 01/2008)|
|6.||Wu, Y L: 3 articles (10/2010 - 01/2008)|
|7.||Chung, Erwin K: 3 articles (06/2007 - 01/2004)|
|8.||Hebert, Lee A: 3 articles (06/2007 - 01/2004)|
|9.||Rovin, Brad H: 3 articles (06/2007 - 01/2004)|
|10.||Yang, Yan: 3 articles (06/2007 - 01/2004)|
|1.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/01/2007 - "A study of association of the complement C4 mutations with systemic lupus erythematosus in the Malaysian population."
01/01/1993 - "[Molecular biology studies of complement C4 gene in patients with systemic lupus erythematosus]."
01/01/2015 - "Complement C4 induces regulatory T cells differentiation through dendritic cell in systemic lupus erythematosus."
07/01/2010 - "Complement C4 null alleles have shown association with a number of diseases including systemic lupus erythematosus (SLE). "
07/01/2009 - "Complete deficiency of complement C4 is among the strongest genetic risk factors for human systemic lupus erythematosus (SLE). "
12/01/2012 - "All laboratory and imaging findings were normal, besides the low levels of C4 complement component were 4.56 mg/dl (normal values 10-40), functional C1-esterase INH was 10.29% (normal values 80-130) C1-estrease inhibitor (protein) 4.58 mg/dl (normal values 16-33), indicating HAE typ I. Regardless of negative medical history in the family of hereditary angioedema, de novo mutation most probably led to her being the first case in the family. "
02/01/2004 - "This report describes a patient with hereditary angioedema (HAE) in whom complement C4 values were consistently normal. "
02/01/2004 - "Normal complement C4 values do not exclude hereditary angioedema."
07/01/1996 - "A diagnosis of hereditary angioedema was made based on the patient's and family's history and on decreased levels of C1 INH and complement component 4. Standard prophylactic methods were contraindicated due to potential teratogenic effects. "
01/01/1988 - "The importance of the examination of C1 inactivator (quantitatively and qualitatively) and of C4 complement fraction in patients with hereditary angioneurotic edema is pointed out."
|3.||Hypertension (High Blood Pressure)
08/01/2000 - "Renal function improved, hypertension was controlled and serum levels of C3 and C4 complement components returned to normal within three months. "
11/01/1995 - "Moreover, patients with essential hypertension and LVH had the highest incidence of specific (anticardiac, ACA) and nonspecific autoantibodies and the highest C3c and C4 complement component levels compared to patients without LVH or the control group. "
01/01/1982 - "M, G, and A immunoglobulins as well as C3 and C4 complement fractions were determined in 20 patients with essential hypertension: all the values were in the normal range. "
01/01/1977 - "Nevertheless, there remains a relatively large isiopathic group which, though possibly heterogeneous, displays a number of characteristic clinical and pathologic features including the following: 1. Steroid-resistant nephrotic syndrome; 2. Hematuria and hypertension; 3. Normal serum complement; 4. Progressive renal insufficiency; 5. Typical pathologic lesion most common in or restricted to juxtamedullary cortex; 6. Absence of clearly defined evidence of immune complex deposition by immunofluorescent or electron microscopic studies; 7. Recurrence of the lesion following renal transplantation. "
05/01/2000 - "[Evaluation of complement component C4 concentration and immunoglobulins IgA, IgG, and IgM in serum of patients with primary essential hypertension]."
01/01/2012 - "After being compared with SLE patients without CVD, the patients with both SLE and CVD were more likely to have elevated serum creatinine, proteinuria, the presence of anti-Sm antibody and decreased complement 4 (C4) levels (P < 0.05). "
01/01/2012 - "Even though she did not satisfy the American College of Rheumatology criteria for diagnosing SLE, she had anemia, proteinuria, elevated erythrocyte sedimentation rate, low complement 4 (C4) levels, and strongly positive antinuclear antibody titer. "
01/01/1994 - "The statistical analysis of repeated measures of a series of biological markers of LN, monitored over the course of the study, evidenced a significant improvement of serum creatinine (p < 0.05), C3 and C4 complement components (p < 0.05), 24-hour proteinuria (p < 0.02) and ESR values (p < 0.05). "
08/01/2012 - "Factors associated with proliferative LN were male gender (p = 0.049), haematuria on dipstix (p < 0.0001), proteinuria on dipstix (p = 0.042), low serum albumin (p = 0.032), low complement C3 (p < 0.0001), low complement C4 (p = 0.009) and positive double-stranded DNA (p = 0.039). "
01/01/1986 - "A high prevalence (71%) of B8/Dw3 was found among male RA patients of the PE group in whom the joint disease had begun at an age over 50 years and who also had besides pleuritis other intrathoracic manifestations of RA associated with high rheumatoid factor titres and low complement (C4) levels in sera. "
11/01/1982 - "Manifestations included pleurisy in five of six patients, rashes in three, nephritis in two, and neurologic disturbances in two; lupus erythematosus cells were found in five patients, antinuclear antibodies in all six, antideoxyribonucleic acid in three, positive Coombs' test results for three patients, and low C4 complement in five of the six. "
06/01/2012 - "To test the anti-inflammatory efficacy of corn silk extract (CSEX) in a rat model of carrageenin (Cg)-induced pleurisy, exudate formation, and cellular infiltration, tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), vascular endothelial growth factor alpha (VEGF-α), interleukin-17 (IL-17), C3 and C4 complement protein levels, adhesion molecule (ICAM-1) and inducible nitric oxide synthase (iNOS) levels, nuclear factor kappa B (NF-κB) activation, and total antioxidant activity were studied, respectively. "
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Biological Markers (Surrogate Marker)
|4.||Interleukin-1beta (Interleukin 1 beta)
|5.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Interleukin-17 (Interleukin 27)
|9.||NF-kappa B (NF-kB)
|4.||Renal Replacement Therapy (Therapies, Renal Replacement)